Maze Therapeutics reported Phase 2 top-line results for MZE829, its once-daily oral dual-mechanism APOL1 inhibitor in patients with broad APOL1-mediated kidney disease (AMKD). At week 12, Maze said the drug achieved an average 35.6% reduction in urine protein (uACR), with stronger outcomes in subgroups including focal segmental glomerulosclerosis.